Looking Ahead: What's Next for Hematology/Oncology in 2022?

[...]because of the pandemic, many centers are experiencing staffing shortages in their clinical trial offices, leading to longer times for opening trials and, in some cases, halting new enrollments. Tixagevimab in combination with cilgavimab (Evusheld) is a new SARS-CoV-2 spike protein-directed attachment inhibitor that has gained emergency use authorization for individuals who are moderately to severely immunocompromised because of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination. Clinical trials of this monoclonal antibody combination showed a reduction in symptomatic SARS-CoV-2 illness as well as severe illness or death in the treatment arm.